MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler® and Ventolin® MDI in Stable Asthma Patients

NCT01076322 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2010-08-12

No results posted yet for this study

Summary

This is an open-label, randomized, cross-over, active-controlled study to evaluate the efficacy and safety effects using Meptin® Swinghaler and Ventolin® MDI in stable asthma patients.

Conditions

Interventions

DRUG

Meptin® Swinghaler

Meptin® Swinghaler® * Ingredient: Procaterol HCL * Dosage form: 10g/puff * Dose(s): 10g * Dosing schedule: 20g (total 20g)

DRUG

Ventolin® MDI

Ventolin® MDI * Ingredient: Salbutamol sulfate * Dosage form: 100g/puff * Dose(s): 100g * Dosing schedule: 200g (total 200g)

Sponsors & Collaborators

  • Taiwan Otsuka Pharm. Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Ping-Hung Kuo, MD · National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01076322 on ClinicalTrials.gov